

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Canceled)
13. (Canceled)
14. (Canceled)
15. (Canceled)
16. (Canceled)
17. (Canceled)
18. (Canceled)
19. **(Currently amended)** A method for producing a high titer antibody producing cell *in vitro* comprising ~~suppressing the expression of alpha-1 anti-trypsin, or endothelial monocyte activating polypeptide I, or both in an antibody producing cell,~~ introducing into an antibody-producing mammalian cell a polynucleotide that disrupts the function of a gene encoding alpha-1-antitrypsin, a polynucleotide that disrupts the function of a gene encoding endothelial monocyte activating polypeptide I, or both, wherein such that the cell expresses a higher titer of an antibody as compared with identical cells into which said polynucleotide that disrupts the function of a gene encoding alpha-1-antitrypsin, said polynucleotide that disrupts the function of a gene encoding endothelial monocyte activating polypeptide I, or both has not been introducedin which such suppression has not occurred.

20. **(Original)** The method of claim 19 wherein the cell is a hybridoma.
21. **(Withdrawn)** The method of claim 19 where in the cell is an epithelial cell.
22. **(Withdrawn)** The method of claim 19 where in the cell is ovarian.
23. **(Withdrawn)** The method of claim 19 where in the cell is a kidney cell.
24. **(Withdrawn)** The method of claim 19 where in the cell is a myeloid cell.
25. **(Withdrawn)** The method of claim 19 where in the cell is a lymphoid cell.
26. **(Canceled)**
27. **(Withdrawn; currently amended)** The method of claim 19 ~~26~~ wherein the polynucleotide that disrupts the function of a gene encoding alpha-1-antitrypsin comprises an expression vector comprising an antisense transcript to a gene encoding alpha-1-antitrypsin and wherein the polynucleotide that disrupts the function of a gene encoding endothelial monocyte activating polypeptide I, suppressing ~~comprises introducing into the cell an~~ expression vector comprising an antisense transcript to a gene ~~genes~~ encoding endothelial monocyte-activating polypeptide I, ~~alpha-1-anti-trypsin, or both.~~
28. **(Currently amended)** The method of claim 19 wherein said polynucleotide that disrupts the function of a gene encoding alpha-1-antitrypsin comprises the suppressing ~~comprises introducing into the cell a knock out targeting vector to disrupt the function of a~~ gene ~~genes encoding endothelial monocyte activating polypeptide I, alpha-1-anti-trypsin and~~ wherein the polynucleotide that disrupts the function of a gene encoding endothelial monocyte activating polypeptide I comprises a knock out targeting vector to disrupt the function of a gene encoding endothelial monocyte activating polypeptide I, or both.
29. **(Canceled)**
30. **(Canceled)**
31. **(Canceled)**
32. **(Canceled)**
33. **(Canceled)**
34. **(Canceled)**
35. **(Canceled)**
36. **(Canceled)**
37. **(Canceled)**
38. **(Canceled)**

**DOCKET NO.:** MOR-0241  
**Application No.:** 10/624,631  
**Office Action Dated:** August 29, 2007

**PATENT**

- 39. (Canceled)
- 40. (Canceled)
- 41. (Canceled)
- 42. (Canceled)
- 43. (Canceled)
- 44. (Canceled)
- 45. (Canceled)
- 46. (Canceled)
- 47. (Canceled)
- 48. (Canceled)
- 49. (Canceled)
- 50. (Canceled)
- 51. (Canceled)
- 52. (Canceled)
- 53. (Canceled)
- 54. (Canceled)
- 55. (Canceled)
- 56. (Canceled)
- 57. (Canceled)
- 58. (Canceled)
- 59. (Canceled)
- 60. (Canceled)
- 61. (Canceled)
- 62. (Canceled)
- 63. (Canceled)
- 64. (Canceled)
- 65. (Canceled)
- 66. (Canceled)
- 67. (Canceled)
- 68. (Canceled)
- 69. (Canceled)

**DOCKET NO.:** MOR-0241

**PATENT**

**Application No.:** 10/624,631

**Office Action Dated:** August 29, 2007

70. (Canceled)

71. (Canceled)

72. (Previously Presented) The method of claim 19, wherein the cell is a rodent cell.

73. (New) The method of claim 19, wherein said alpha-1-antitrypsin comprises an amino acid sequence of SEQ ID NO:21, 22, 23, 24, 25, 26, or 27 and said endothelial monocyte activating polypeptide I comprises an amino acid sequence of SEQ ID NO: 28, 29, 30, 31, 32, 33, or 34.